Brain Cancer | Clinical

June 23, 2022

An investigational bivalent gB/pp65 immunotherapeutic vaccine candidate has been granted orphan drug designation by the FDA for the treatment of patients with glioblastoma.

June 20, 2022

Fast track designation has been granted by the FDA to dianhydrogalactitol for the treatment of patients with newly-diagnosed unmethylated glioblastoma.

June 20, 2022

Paxalisib has been granted orphan drug designation by the FDA for the treatment of patients with atypical rhabdoid or teratoid tumors in rare and aggressive childhood brain cancer.

June 15, 2022

Pediatric low-grade glioma is the most common type of brain tumor found in children with cancer, and there are currently no approved treatments or standard of care to combat it.

June 13, 2022

The phase 3 REVELATE trial investigating potential use of 18F-fluciclovine in detecting recurrent brain metastases after radiotherapy has completed patient accrual.

June 10, 2022

Interim clinical data from a phase 1/2 clinical trial of ST101 in refractory solid tumors leads to the expansion of the phase 2 glioblastoma arm of the study.

June 08, 2022

According to Eric Bouffet, MD, results from a phase 2 study presented during the 2022 ASCO Annual Meeting show how important it is to document as early as possible the molecular alterations that are present in this type of tumor.

June 06, 2022

Dafrafenib plus trametinib demonstrated greatly improved response rates and progression-free survival in pediatric patients with BRAF V600-mutated gliomas.

May 31, 2022

The combination of naxitamab combined with irinotecan, temozolomide, and sargramostim induced responses in patients with high-risk neuroblastoma.

May 27, 2022

After identifying a survival disparity among non-White Hispanic patients with pediatric neuroblastoma, investigators will next examine the interaction of survival and race, ethnicity, and poverty, acknowledging the intersectionality of these factors due to structural racism in the United States.